Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) were down 4.5% during trading on Thursday . The stock traded as low as $3.58 and last traded at $3.59, with a volume of 54,854 shares changing hands. The stock had previously closed at $3.76.

Several analysts have recently commented on ABEO shares. Maxim Group reissued a “buy” rating on shares of Abeona Therapeutics in a research note on Tuesday, May 24th. FBR & Co reissued a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a research note on Sunday, May 22nd. Rodman & Renshaw reissued a “buy” rating and set a $17.00 price target on shares of Abeona Therapeutics in a research note on Wednesday, May 18th. Finally, Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Wednesday, April 27th.

The firm’s market cap is $117.41 million. The stock’s 50-day moving average price is $2.74 and its 200 day moving average price is $2.69.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.04. Equities analysts predict that Abeona Therapeutics Inc. will post ($0.66) EPS for the current year.

An institutional investor recently raised its position in Abeona Therapeutics stock. Royce & Associates LLC raised its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned about 0.92% of Abeona Therapeutics worth $1,007,000 at the end of the most recent quarter.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.